Log In
Print this Print this

TILs (LN-144) (formerly Contego)

  Manage Alerts
Collapse Summary General Information
Company Lion Biotechnologies Inc.
DescriptionAutologous T cell therapy that utilizes tumor infiltrating lymphocytes (TILs) derived from the patient's tumor
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today